News
ENOV
27.39
+1.97%
0.53
Weekly Report: what happened at ENOV last week (1215-1219)?
Weekly Report · 4d ago
Is Enovis’ Extended Debt Maturities And HR Succession Plan Altering The Investment Case For ENOV?
Simply Wall St · 12/18 12:16
Enovis Price Target Cut to $50.00/Share From $58.00 by Canaccord Genuity
Dow Jones · 12/17 20:24
Enovis Is Maintained at Buy by Canaccord Genuity
Dow Jones · 12/17 20:24
Canaccord Genuity Maintains Buy on Enovis, Lowers Price Target to $50
Benzinga · 12/17 20:14
Why Enovis (ENOV) Stock Is Trading Up Today
Barchart · 12/17 12:56
Enovis price target lowered to $50 from $58 at Canaccord
TipRanks · 12/17 12:25
Enovis (ENOV) Gets a Buy from Canaccord Genuity
TipRanks · 12/17 12:08
Enovis Initiated at Buy by Freedom Capital Markets
Dow Jones · 12/17 09:29
Enovis Price Target Announced at $45.00/Share by Freedom Capital Markets
Dow Jones · 12/17 09:29
Enovis (ENOV) Initiated with a Buy at Freedom Capital Markets
TipRanks · 12/16 21:55
Enovis initiated with a Buy at Freedom Capital
TipRanks · 12/16 21:30
50 heavily shorted laggards poised to rebound according to Wells Fargo
Seeking Alpha · 12/16 21:23
Enovis (ENOV): Reworked Credit Agreement Prompts Fresh Look at Turnaround Prospects and Valuation
Simply Wall St · 12/16 20:20
Enovis Announces Leadership Transition in HR Department
TipRanks · 12/15 21:37
Weekly Report: what happened at ENOV last week (1208-1212)?
Weekly Report · 12/15 10:30
1 Volatile Stock for Long-Term Investors and 2 We Turn Down
Barchart · 12/12 08:08
Enovis Amends Credit Agreement for Financial Flexibility
TipRanks · 12/10 11:58
Does Enovis (ENOV) Insider Buying Hint at Management Conviction Despite Recent Net Losses?
Simply Wall St · 12/10 09:33
More
Webull provides a variety of real-time ENOV stock news. You can receive the latest news about Enovis Corp through multiple platforms. This information may help you make smarter investment decisions.
About ENOV
Enovis Corporation is a medical technology company. It is focused on developing clinically differentiated solutions by manufacturing and distributing high-quality medical devices with a range of products used for reconstructive surgery, rehabilitation, pain management and physical therapy. It operates through two segments: Prevention & Recovery and Reconstructive. The Prevention & Recovery segment provides orthopedic and recovery science solutions, including devices, software, and services across the patient care continuum from injury prevention to rehabilitation after surgery, injury, or from degenerative diseases. The Prevention & Recovery products are marketed under several brand names, such as DJO. The Reconstructive segment provides surgical implant solutions, offering a comprehensive suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger and surgical productivity tools. It also operates a Enovis Growth eXcellence business system (EGX).